InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.10
(
-0.47%
)
Bitcoin
54,788.99
(
-1.89%
)
Post# of 252504
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119984
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 194086

Wednesday, 08/19/2015 8:31:02 PM

Wednesday, August 19, 2015 8:31:02 PM

Post# of 252504
MCUR phase-3 trial of CureXcell in venous leg ulcers stopped for futility:

http://finance.yahoo.com/news/macrocure-ltd-provides-futility-analysis-224000889.html

MCUR is also running a phase-3 trial of CureXcell in diabetic foot ulcers, which will report data in4Q15; however, failure of the phase-3 VLU trial probably spells the end of opportunity for MCUR to get CureXcell approved in the US for a broad wound-closure indication—and perhaps for any indication at all. (CureXcell is technically approved in Israel, but it isn’t actively marketed there.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up